Pierre Laurent-Puig
Bill Hait
REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
